Umoja hopes to transform the future of cancer treatment by combining a deep understanding of immune physiology and genetic engineering with the most advanced, integrated cellular immunotherapy platform for cancer treatment currently under development.
Our treatment approach retools a patient’s immune system in vivo to direct potent anti-cancer immune cells to a patient’s tumor, augmenting the body’s natural mechanisms for fighting cancer.
Personalized therapy without complex and costly manufacturing
No lengthy treatment timelines
An “off the shelf” treatment that is accessible to patients everywhere
Umoja is committed to developing therapies that enable all patients to live better, fuller lives without the burden and side effects associated with many current cancer treatments.
We have assembled a diverse, highly skilled, and passionate team that combines specific expertise and experience with in vivo gene transfer, drug development, and oncology.
Latest News
Umoja Biopharma Breaks Ground on Extensive Manufacturing Facility for its Next-Generation CAR T Immunotherapies
Seattle, Wash., August 30, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the groundbreaking of its new development and manufacturing facility in Louisville, Colo. Construction of the state-of-the-art facility is a key milestone for the company and represents an important next step in bringing effective and accessible CAR T therapies to cancer patients.
Umoja Biopharma Appoints Greg Sargen to its Board of Directors
Seattle, Wash., August 24, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointment of Greg Sargen to its Board of Directors.
Umoja Biopharma Expands Management Team with Key Hires in Research and Business Development
Seattle, Wash., July 27, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointments of three new hires in the company’s research and business development functions, including Bruce Kerwin, Ph.D. as Senior Vice President of Process and Product Development, Ryan Larson, Ph.D. as Vice President and Head of Translational Science, and Mike Fitzpatrick as Vice President of Business Development and Operations.